Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms C_ASCENT
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
- 17 Jan 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.